Non-coding RNA in rhabdomyosarcoma progression and metastasis

dc.contributor.authorRamadan, Farah
dc.contributor.authorSaab, Raya H.
dc.contributor.authorHussein, Nader
dc.contributor.authorCleźardin, Philippe
dc.contributor.authorCohen, Pascale A.
dc.contributor.authorGhayad, Sandra E.
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:37:17Z
dc.date.available2025-01-24T11:37:17Z
dc.date.issued2022
dc.description.abstractRhabdomyosarcoma (RMS) is a soft tissue sarcoma of skeletal muscle differentiation, with a predominant occurrence in children and adolescents. One of the major challenges facing treatment success is the presence of metastatic disease at the time of diagnosis, commonly associated with the more aggressive fusion-positive subtype. Non-coding RNA (ncRNA) can regulate gene transcription and translation, and their dysregulation has been associated with cancer development and progression. MicroRNA (miRNA) are short non-coding nucleic acid sequences involved in the regulation of gene expression that act by targeting messenger RNA (mRNA), and their aberrant expression has been associated with both RMS initiation and progression. Other ncRNA including long non-coding RNA (lncRNA), circular RNA (circRNA) and ribosomal RNA (rRNA) have also been associated with RMS revealing important mechanistic roles in RMS biology, but these studies are still limited and require further investigation. In this review, we discuss the established roles of ncRNA in RMS differentiation, growth and progression, highlighting their potential use in RMS prognosis, as therapeutic agents or as targets of treatment. Copyright © 2022 Ramadan, Saab, Hussein, Clézardin, Cohen and Ghayad.
dc.identifier.doihttps://doi.org/10.3389/fonc.2022.971174
dc.identifier.eid2-s2.0-85136966862
dc.identifier.urihttp://hdl.handle.net/10938/28831
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Oncology
dc.sourceScopus
dc.subjectCircrna
dc.subjectLncrna
dc.subjectMirna
dc.subjectNon-coding rnas
dc.subjectPrognosis
dc.subjectRhabdomyosarcoma
dc.subjectRrna
dc.subjectTherapeutic targets
dc.subjectCircular ribonucleic acid
dc.subjectDoxycycline
dc.subjectInterleukin 4
dc.subjectMicrorna 182
dc.subjectMicrorna 192
dc.subjectMicrorna 214
dc.subjectMicrorna 29
dc.subjectMicrorna 375
dc.subjectRibosome rna
dc.subjectSomatomedin c receptor
dc.subjectUntranslated rna
dc.subjectAngiogenesis
dc.subjectApoptosis
dc.subjectBioinformatics
dc.subjectCancer prognosis
dc.subjectCarcinogenesis
dc.subjectCardiovascular disease
dc.subjectEpithelial mesenchymal transition
dc.subjectExosome
dc.subjectGenetic transcription
dc.subjectHuman
dc.subjectImmunomodulation
dc.subjectMapk signaling
dc.subjectMetastasis
dc.subjectMicroarray analysis
dc.subjectReal time polymerase chain reaction
dc.subjectReview
dc.subjectRna translation
dc.subjectTumor growth
dc.subjectUpregulation
dc.subjectWestern blotting
dc.titleNon-coding RNA in rhabdomyosarcoma progression and metastasis
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1538.pdf
Size:
2.68 MB
Format:
Adobe Portable Document Format